Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F11%3A00358495" target="_blank" >RIV/61389013:_____/11:00358495 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jconrel.2010.10.011" target="_blank" >http://dx.doi.org/10.1016/j.jconrel.2010.10.011</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jconrel.2010.10.011" target="_blank" >10.1016/j.jconrel.2010.10.011</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins

Popis výsledku v původním jazyce

Adenovirus (Adluc) was coated with a reactive polymer based on poly[N-(2-hydroxypropyl)methacrylamide] to ablate normal infection pathways. Linkage of a monoclonal antibody against E-selectin demonstrated E-selectin-specific transduction of tumour necrosis factor-? (TNF-?)-activated endothelial cells. A two-component targeting system using protein G was developed. We report an enhancement in transduction of TNF-?-activated endothelium in vitro and ex vivo in a human umbilical vein cord model using the E-selectin antibody. Virus retargeted using a chimeric P-selectin Glycoprotein Ligand-1-Fc fusion (PSGL-1) protein showed better circulation kinetics and uptake into HepG2 xenografts following systemic administration in mice, with 36-fold higher genome copies, compared with non-modified virus. Immunohistochemistry of tumour sections from mice treated with PSGL-1-retargeted virus showed a co-localisation of luciferase with CD31 suggesting selective endothelial targeting.

Název v anglickém jazyce

Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins

Popis výsledku anglicky

Adenovirus (Adluc) was coated with a reactive polymer based on poly[N-(2-hydroxypropyl)methacrylamide] to ablate normal infection pathways. Linkage of a monoclonal antibody against E-selectin demonstrated E-selectin-specific transduction of tumour necrosis factor-? (TNF-?)-activated endothelial cells. A two-component targeting system using protein G was developed. We report an enhancement in transduction of TNF-?-activated endothelium in vitro and ex vivo in a human umbilical vein cord model using the E-selectin antibody. Virus retargeted using a chimeric P-selectin Glycoprotein Ligand-1-Fc fusion (PSGL-1) protein showed better circulation kinetics and uptake into HepG2 xenografts following systemic administration in mice, with 36-fold higher genome copies, compared with non-modified virus. Immunohistochemistry of tumour sections from mice treated with PSGL-1-retargeted virus showed a co-localisation of luciferase with CD31 suggesting selective endothelial targeting.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EI - Biotechnologie a bionika

OECD FORD obor

—

Projekt

<a href="/cs/project/1M0505" target="_blank" >1M0505: Centrum cílených terapeutik</a><br>

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Controlled Release

ISSN

0168-3659

e-ISSN

—

Svazek periodika

150

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

196-203

Kód UT WoS článku

000289701200010

EID výsledku v databázi Scopus

—